US States can save billions through biosimilar medicines; report

14 October 2021

The Biosimilars Forum, in partnership with the Pacific Research Institute PRI), released a report and interactive tool highlighting the billions of dollars that biosimilars can save states.

Californians could save more than $1 billion annually with a 75% biosimilar market share. Similarly, Floridians could save more than $960 million, and Texans and New Yorkers could save more than $820 million.

The new report and interactive savings tool highlight projected state savings for patients, taxpayers, and employers associated with a 75% adoption rate of biosimilars, which could result from commonsense, bipartisan policy changes.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK